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Abstract
Background: The appropriate control of mitotic entry and exit is reliant on a series of interlocking signaling events that
coordinately drive the biological processes required for accurate cell division. Overlaid onto these signals that promote
orchestrated cell division are checkpoints that ensure appropriate mitotic spindle formation, a lack of DNA damage,
kinetochore attachment, and that each daughter cell has the appropriate complement of DNA. We recently discovered that
AMP-activated protein kinase (AMPK) modulates the G2/M phase of cell cycle progression in part through its suppression of
mammalian target of rapamycin (mTOR) signaling. AMPK directly phosphorylates the critical mTOR binding partner raptor
inhibiting mTORC1 (mTOR-raptor rapamycin sensitive mTOR kinase complex 1). As mTOR has been previously tied to
mitotic control, we examined further how raptor may contribute to this process.
Methodology/Principal Findings: We have discovered that raptor becomes highly phosphorylated in cells in mitosis.
Utilizing tandem mass spectrometry, we identified a number of novel phosphorylation sites in raptor, and using phospho-
specific antibodies demonstrated that raptor becomes phosphorylated on phospho-serine/threonine-proline sites in
mitosis. A combination of site-directed mutagenesis in a tagged raptor cDNA and analysis with a series of new phospho-
specific antibodies generated against different sites in raptor revealed that Serine 696 and Threonine 706 represent two key
sites in raptor phosphorylated in mitosis. We demonstrate that the mitotic cyclin-dependent kinase cdc2/CDK1 is the kinase
responsible for phosphorylating these sites, and its mitotic partner Cyclin B efficiently coimmunoprecipitates with raptor in
mitotic cells.
Conclusions/Significance: This study demonstrates that the key mTOR binding partner raptor is directly phosphorylated
during mitosis by cdc2. This reinforces previous studies suggesting that mTOR activity is highly regulated and important for
mitotic progression, and points to a direct modulation of the mTORC1 complex during mitosis.
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Introduction
The serine/threonine protein kinase mammalian target of
rapamycin (mTOR) is a key mediator of the cellular response to
nutrient status through its regulation of translation, ribosome
biogenesis, mitochondrial metabolism, and autophagy [1]. mTOR
is present in one of two complexes within the cell: mTORC1 is
defined by raptor, GbL/mLST8, and negative regulatory subunits
PRAS40 and DEPTOR, whereas mTORC2 contains rictor,
mSin1, and Protor as well as GbL/mLST8 and DEPTOR [2].
The best-established substrates of mTORC1 demonstrate the
importance of mTOR in translational control. mTOR phosphor-
ylates S6K1 at T389 to enhance S6K1 activity, which amongst
other things phosphorylates the S6 subunit of the ribosome to
promote translation. mTOR also phosphorylates 4EBP1, causing
its dissociation from its binding partner eIF4E, which is then free
to associate with the cap-complex to promote cap-dependent
translation [3].
The activity of mTORC1 is dependent on the small Ras-like
GTPase, Rheb, whose GTP-loaded state is regulated by a
GTPase-accelerating protein (GAP) complex composed of the
TSC1 and TSC2 tumor suppressors. Inputs from a variety of
pathways converge on the TSC1/2 complex to regulate
mTORC1 signaling [4]. Following growth factor stimulation,
Akt, Erk and Rsk can phosphorylate and inactivate TSC2, leading
to activation of mTORC1. Under conditions of low ATP, the
energy-sensing kinase AMPK is activated and phosphorylates and
activates TSC2, inhibiting mTORC1.
In addition to the hub of signaling at TSC2, phosphorylation of
components of mTORC1 have recently been shown to have
important regulatory roles in mTOR signaling [5,6,7,8,9,10,11].
PRAS40 is a substrate of both Akt and mTOR, where upon
phosphorylation, PRAS40 dissociates from mTORC1, relieving
inhibition of mTORC1 activity following growth factor stimula-
tion. mTOR also phosphorylates the recently identified mTORC1
component DEPTOR, marking it for degradation and further
alleviating inhibition of mTORC1 [2]. Raptor (regulatory
associated protein of TOR) is thought to act as the key mTORC1
scaffolding protein that binds mTOR substrates via the TOR
signaling (TOS) motif, facilitating their phosphorylation by
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importance of phosphorylation of raptor on various sites in the
regulation of mTOR signaling by pro- and anti-proliferative
signals. Phosphorylation by Rsk at S721 as well as by mTOR at
S863 have been shown to enhance mTORC1 activity [11],
whereas phosphorylation at S722 and S792 by AMPK create 14-
3-3 binding sites and inhibit mTORC1 activity [10]. The exact
mechanism of augmentation or inhibition of mTOR activity by
raptor phosphorylation remains elusive.
We have shown previously that under energy stress conditions,
fewer cells proceed into G2/M and that this cell cycle arrest is
dependent on AMPK phosphorylation of raptor and inhibition of
mTORC1 activity. This suggested that perhaps mTOR signaling
might play a role in mitosis, as suppression of mTOR blocks entry
into G2/M and inappropriate activation of mTOR signaling drives
cells into G2/M. In our investigations into the regulation of mTOR
signaling in mitosis, we identified several sites in raptor phosphor-
ylated by Cdc2 that may play a role in mitotic progression.
Materials and Methods
Antibodies and Plasmids
Myc-raptor, AU1-mTOR, HA-GbL and Flag-PRAS40 originated
in Dr. David Sabatini’s Lab (MIT, Cambridge, MA) and were
obtained from Addgene.org (Cambridge, MA). Ha-tagged 4ebp1 and
S6K1 were obtained from Dr. John Blenis (Harvard Medical School,
Boston, MA). Myc-raptor was subcloned into pENTR3C (Invitrogen),
and serine to alanine point mutations were made using QuikChange
II XL (Stratagene). Mutant alleles were then put into an FBneo DEST
vector by LR reaction (Invitrogen). All constructs were fully sequence
verified. Phospho-Plk1 T210 was from BD Pharmingen (#558400).
Phospho-raptor (S696, T706, S863, S877) and Phospho-histone H3
antibodies were obtained from Millipore. Anti-raptor used for
endogenous raptor immunoprecipitations was from Invitrogen
(#42-4000). The 9E10 anti-myc antibody was used for immunopre-
cipitations (Roche). Antibodies against raptor (#2280), mTOR
(#2983), GbL (#3274), PRAS40 (#2610), phospho-S6K T389
(#9234), pAurora A, B, C (T288/T232/T198) (#2914), Cyclin B1
(#4138), phospho-4EBP1 (T37/46) (#2855), phospho-4EBP1 (S65)
(#9451), myc-tag (#2272), phospho-threonine-proline (#2321), and
GST-tag (#2622) were from Cell Signaling Technologies.
Cell Culture
Hela, A549 and HEK293T cells were grown in DMEM with
10% FBS at 37u with 5% CO2. Cells were transfected with
Lipofectamine 2000 (Invitrogen) as per manufacturer’s instruction
for 32–36 hours. Nocodazole (1 ug/mL) (SIGMA) or taxol (1 uM)
(Cell Signaling Technologies) treatment was administered for 16–
18 hours prior to lysis (usually 16 h post-transfection). Replace-
ment of endogenous raptor with myc-tagged raptor was achieved
by infecting Hela cells with a retrovirus expressing myc-wt or myc-
S696/T706/S711AAA raptor in the FBneo vector, and selection in
neomycin. These stables were subsequently infected with a lentivirus
expressing a short-hairpin RNA that targets the 39 UTR of
human raptor in the pLKO vector and selected in puromycin
and distributed by Addgene (,http://www.addgene.org/pgvec1?f=
c&identifier=1858&atqx=raptor&cmd=findpl.). A549 cells were
synchronized in G1/S by double thymidine block as follows: 2 mM
thymidine was added to the media for 14–16 hours, plates were
w a s h e dt w i c ew i t hP B S ,t h e nc o m p l e t et h y m i d i n e - f r e em e d i aw a s
added. Eight to ten hours later, 2 mM thymidine was added again
for 14–16 hours, cells were washed twice with PBS, then released
into thymidine-free media. 50 uM roscovitine was administered for
6 hours following 16 hours nocodazole treatment in A549 cells.
Torin1 (50 nM) (Dr. D. Sabatini, MIT) was added for 1 h.
Biochemistry
For immunoprecipitations, cells were washed with ice cold PBS
and collected in lysis buffer 1 (20 mM Tris pH 7.5, 150 mM NaCl,
1% Triton X-100, 50 mM NaF, 1 mM EDTA, 1 mM EGTA,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
10 nM Calyculan A, and EDTA-free complete protease inhibitor
tablets (Roche) as per manufacturer’s directions) for experiments in
Figures 1, 2, 3, 4a and 4b or lysis buffer 2 (40 mM HEPES pH 7.5,
150 mM NaCl, 0.3% CHAPS, 50 mM NaF, 1 mM EDTA, 1 mM
EGTA, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophos-
phate, 10 nM Calyculan A and EDTA-free complete protease
inhibitor tablets) for Figures 4c and 5. Lysates were incubated on ice
for 15 minutes after lysis, then spun at 13,200 rpm at 4uC for
15 minutes. The supernatants were collected and normalized for
protein levels by BCA assay (Pierce). Whole cell lysates were
incubated with antibodies for 1.5 hours with constant rocking at
4uC, then protein-A or –G sepharose beads (Invitrogen) were added
for 1 hour. Immunoprecipitates were washed three times with lysis
buffer, and sample buffer was added to 1X final, and samples were
boiled at 95uC for 5 minutes. Helas were lysed in boiling SDS-lysis
buffer (10 mM Tris pH 7.5, 100 mM NaCl, 1% SDS) and
equilibrated by BCA assay. Samples were resolved on 8–12%
SDS-PAGE gels, transferred to PVDF and immunoblotted
according to the antibody manufacturer’s instructions.
Phosphatase Treatment
Anti-myc immunoprecipitations were performed on cell lysates
from HEK293T cells transiently transfected with myc-raptor
treated with or without nocodazole. After washing the beads twice
in lysis buffer 1, they were washed twice in CIAP buffer (50 mM
Figure 1. Raptor is phosphorylated on S/T*-P sites in cells
treated with nocodazole. (A) Raptor undergoes a mobility shift on
SDS-PAGE following nocadazole which is collapsed by phosphatase
treatment. Myc-tagged raptor was expressed in HEK293T cells and
nocadazole treated for 16 h. Where indicated, immunoprecipitates were
treated with or without calf-intestinal alkaline phosphatase (CIP) and
then resolved in SDS-PAGE, and subjected to anti-myc immunoblotting.
(B) Raptor is recognized by a phospho-threonine proline antibody in
mitotic arrested cells. HEK293T cells transiently expressing myc-tagged
raptor were treated for 16 h with taxol and immunoprecipitates were




PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9197Figure2.Massspectrometryanalysisofraptorrevealsseveralnovelphosphorylationsites.(A)Phosphorylationsitesinraptorafternocodazole
treatment as detected by LC/MS/MS. The presence of a phosphate moiety is indicated by a magenta colored box. Note that four serine-or threonine sites
followed by a proline were detected in this analysis. Sites of oxidation (green) and deamidation (blue) represent in vitro artifacts of the mass spectrometry
experiment. (B). Schematic of human raptor domain structure with all known phosphorylation sites found in this and previous studies (for full detailss e e
Table S1). Note that most phosphorylation sites cluster in two regions of the protein. (C) Conservation of the indicated phosphorylation sites.
doi:10.1371/journal.pone.0009197.g002
cdc2 Phosphorylates Raptor
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intestinal alkaline phosphatase (CIAP) (NEB) with constant
agitation at 37uC for 30 minutes.
In Vitro Kinase Assays
Anti-myc immunoprecipitations from HEK293T cells tran-
siently transfected with myc-raptor for 16 hours followed by 12
hours of 2 uM hydroxyurea treatment were washed three times
with lysis buffer 1, then three times with kinase buffer (25 mM Tris
pH 7.5, 10 mM MgCl2, 0.1 mM Na3VO4, 5 mM b-glycerophos-
phate, 2 mM DTT). Immunoprecipitates were then incubated
with 20 uL kinase reaction mix (kinase buffer, 10 uM ATP) with
or without 175 ng recombinant Cdc2/cyclin B (Cell Signaling
Technologies #7518) at 30u for 30 minutes with constant shaking.
Reaction was quenched by addition of sample buffer to 1X and
boiling at 95u for 5 minutes.
LC/MS/MSTandem Mass Spectrometry
For all mass spectrometry (MS) experiments, myc-Raptor
immunoprecipitates were separated using SDS-PAGE, the gel
was stained with Coomassie blue, and the myc-Raptor band was
excised. Samples were subjected to reduction with dithiothreitol,
alkylation with iodoacetamide, and in-gel digestion with trypsin or
chymotrypsin overnight at pH 8.3, followed by reversed-phase
microcapillary/tandem mass spectrometry (LC/MS/MS). LC/
MS/MS was performed using an Easy-nLC nanoflow HPLC
(Proxeon Biosciences) with a self-packed 75 mm id x 15 cm C18
column connected to a LTQ-Orbitrap XL mass spectrometer
(Thermo Scientific) in the data-dependent acquisition and positive
ion mode at 300 nL/min. MS/MS spectra collected via collision
induced dissociation in the ion trap were searched against the
concatenated target and decoy (reversed) single entry Raptor and
full Swiss-Prot protein databases using Sequest (Proteomics
Browser Software, Thermo Scientific) with differential modifica-
tions for Ser/Thr/Tyr phosphorylation (+79.97) and the sample
processing artifacts Met oxidation (+15.99), deamidation of Asn
and Gln (+0.984) and Cys alkylation (+57.02). Phosphorylated and
unphosphorylated peptide sequences were identified if they
initially passed the following Sequest scoring thresholds against
the target database: 1+ ions, Xcorr $2.0 Sf $0.4, P$5; 2+ ions,
Figure 3. Raptor is phosphorylation on Ser696 and Thr706 during mitosis. (A) The mitotic induced bandshift is collapsed by mutation of
Ser696, Thr706, and Thr711. Indicated serine/threonine-to-alanine non-phosphorylatable raptor mutants were expressed in HEK293T cells treated
with taxol as in Figure 1. (b, c) Wild-type or non-phosphorylatable raptor alleles were immunoprecipitated from nocadazol treated HEK293T cells and
then immunoblotted with indicated site-specific phospho-raptor antibodies. Note specificity of each antisera and that Ser696 and Thr706, but not
Ser863 or Ser877 are increased by nocadazole treatment.
doi:10.1371/journal.pone.0009197.g003
cdc2 Phosphorylates Raptor
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9197Figure 4. Cdc2 is the raptor Ser696, Thr706 kinase. (A) Purified cdc2 can directly phosphorylate raptor on Thr706 and Ser696 in vitro. Myc-
raptor (wild-type or S696/T706AA) was immunoprecipitated from hydroxyurea treated HEK293T cells. Immunoprecipitates were incubated with or
without active recombinant Cdc2/cyclin B and immunoblotted with phospho-raptor Ser696, Thr706 or total raptor. (B) Endogenous raptor is
phosphorylated on Thr706 in synchronized cells undergoing mitosis, and this phosphorylation is blocked by the CDK inhibitor roscovitine. A549 cells
were synchronized by double thymidine block and endogenous raptor was immunoprecipitated at the indicated times after release with an anti-
raptor antibody and immunoblotted with phospho-raptor Thr706. Whole cell lysates taken from the same cells were immunoblotted for mitotic
markers phospho-histone H3 Ser10 and phospho-Plk1 Thr210. (C) Raptor immunoprecipitates with endogenous cyclin B. Hela cells stably expressing
myc-wt raptor with stable knockdown of endogenous raptor treated with or without taxol for 16 hours. myc-tagged raptor was immunoprecipitated
and immunoblotted for Cyclin B.
doi:10.1371/journal.pone.0009197.g004
cdc2 Phosphorylates Raptor
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9197Figure 5. Cdc2 phosphorylation of raptor does not change mTORC1 complexes or signaling. (A) HEK293T cells were transiently
transfected with myc-raptor (wild-type or Ser696/Thr706/Ser711AAA: ‘‘3A’’), AU1-mTOR, HA-GbL and Flag-PRAS40 for 16 hours, followed by 16 hours
of nocodazole treatment following addition of fresh media to plates. Cells were lysed and myc-raptor was immunoprecipitated using an antibody
against the myc-tag. Immunoprecipitates were resolved by SDS-PAGE and probed with antibodies against the Flag- and HA- tags. (B,C) HEK293T cells
were transiently transfected with myc-raptor (wild-type or 3A) and Flag-S6K or Flag-4EBP1. 16 hours later, media was changed and nocodazole was
added for 16 hours. Cells were lysed and lysated were split in two; myc-raptor was immunoprecipitated with an antibody against the myc-tag, and
Flag-S6K or 4EBP1 were immunoprecipitated with an antibody against the Flag-tag. Immunoprecipitates were resolved by SDS-PAGE and
immunoblotted with indicated antibodies. (D) Hela cells stably expressing myc-raptor (wt or 3A) with stable knockdown of endogenous raptor were
treated with nocodazole for 16 hours, then Torin1 or roscovitine were added for 4 hours. Cells were lysed and myc-raptor was immunoprecipitated
with an antibody against the myc-tag. Immunoprecipitates were resolved by SDS-PAGE and immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0009197.g005
cdc2 Phosphorylates Raptor
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against the target protein database. Passing MS/MS spectra were
manually inspected to be sure that all b- and y- fragment ions
aligned with the assigned sequence and modification sites.
Determination of the exact sites of phosphorylation was aided
using FuzzyIons and GraphMod and phosphorylation site maps
were created using ProteinReport software (Proteomics Browser
Software suite, Thermo Scientific). False discovery rates (FDR) of
peptide hits (phosphorylated and unphosphorylated) were estimat-
ed below 1.5% based on reversed database hits.
Results
Raptor Is Phosphorylated on S/T-P Sites in Cells Stalled in
Mitosis with Nocodazole
We have shown previously that cells undergoing energy stress
arrest in G2/M and that if they lack the ability to downregulate
mTORC1 signaling during energy stress, they proceed inappro-
priately into mitosis [10]. In the course of further examining how
mTORC1 signaling is regulated during mitosis, we observed that
stalling cells in mitosis through use of the microtubule destabilizing
drug nocodazole caused a shift in the mobility of raptor on SDS-
PAGE, and this was reversed by in vitro phosphatase treatment of
the immunoprecipitates (Figure 1a). Similar results were also seen
with the microtubule stabilizing drug taxol, which also promotes
mitotic arrest (Figure 1b). Phosphorylation-induced mobility shifts
are often indicative of phosphorylation on serine/threonine-
proline residues, and indeed we see an increase in immunoreac-
tivity of an anti-phospho-threonine-proline antibody on raptor
immunoprecipitates isolated from arrested cells compared to
asynchronous cells (Figure 1b).
Mass Spectrometry Analysis of Raptor Reveals Several
Novel In Vivo Phosphorylation Sites
In attempts to identify the residues of raptor responsible for the
nocodazole-induced bandshift, microcapillary liquid-chromatog-
raphy/tandem mass spectrometry (LC/MS/MS) was performed
on raptor immunoprecipitated from cells with or without
nocodazole treatment. We identified several novel phosphoryla-
tion sites from this analysis, including Ser696, Thr706, Ser738,
Ser771 and Ser877 (Figure 2a, Table S1). Of these sites, Ser696,
Thr706, Ser771, and Ser863, Ser877 are S*-P sites, all of which
are evolutionarily conserved through vertebrates (Figure 2b).
Interestingly, mapping our phosphorylation sites along with all
those from phospho-proteomic databases including PhosphoSite-
Plus (www.phosphosite.org; [12]) reveals that phosphorylation sites
within raptor cluster to two regions located between the HEAT
repeat region and the WD-repeat containing C-terminal of raptor
(Figure 2c).
Raptor Is Phosphorylated on Ser696 and T706 during
Mitosis
Next we examined whether mutation of any of the identified
serine/threonine-proline sites to alanine would alter the mobility
shift induced in raptor upon nocodazole or taxol treatment. From
this analysis, we discovered that an allele of raptor with mutation
of Ser696 and Thr706 to alanine, showed reduced band-shifting
(Figure 3a). Mutation of the adjacent serine-proline residue,
Ser711, to alanine in combination with 696/706 was found to
further collapse the bandshift, suggesting that S711 is also
phosphorylated in cell blocked in mitosis. Mutation of other
reported S/T*-P sites in raptor did not collapse the bandshift
(Fig. 3a, data not shown).
To directly determine the residues of raptor up-regulated
following nocodazole treatment, phospho-specific-antibodies
against Ser696, Thr706, Ser877, and Ser863 were generated
and verified as recognizing only wild-type myc-tagged raptor
immunoprecipitated from HEK293T cells, but not raptor mutated
at the specified phospho-acceptor residue (Figure 3b, c).
Treatment with nocodazole to block cells in mitosis greatly
increased phosphorylation of raptor on Ser696 and Thr706
(Figure 3b) but notably, not any of the other S/T*-P sites tested
(Figure 3c).
Cdc2 Is the Raptor Ser696, Thr706 Kinase
Having identified several residues of raptor phosphorylated in
cells blocked in mitosis, we next sought to identify the upstream
kinase for Ser696 and Thr706. Knowing the upstream kinase was
active following nocodazole treatment, and was proline-directed,
we decided to examine the mitotic CDK family member Cdc2.
First we tested whether recombinant Cdc2-cyclin B kinase
complexes were capable of in vitro phosphorylation of raptor
immunoprecipitated from hydroxyurea treated HEK293T cells
(and hence derived from cells where Cdc2 would be inactive)
(Figure 4a). Indeed cdc2/cyclin B induced robust phosphorylation
of raptor in vitro on Thr706 and Ser696.
To examine whether Phospho-Thr706 can be detected during
natural mitotic progression and is not simply due to kinases
activated by microtubulestress, we synchronized A549 cells using
double thymidine block and endogenous raptor was immuno-
precipitated at various timepoints following thymidine release
and immunoblotted with the phospho-raptor Thr706 antibody
(Figure 4b). Mitotic entry peaked at 8 to 10 hours following
thymidine release in these cells as demarcated by increased
mitotic markers phospho-histone H3 and phospho-Plk1, coin-
ciding exactly with maximal Thr706 phosphorylation on
endogenous raptor (Fig 4b). Importantly, endogenous raptor
phosphorylation was observed during mitosis in the synchronized
cells similar to that observed following nocadozole treatment
when all of the cells are arrested in mitosis. We further examined
cdc2 involvement through acute treatment of nocodazole
arrested cells with the cdc2 inhibitor roscovitine. Roscovitine
resulted in inhibition of endogenous phospho-raptor Thr706
(Fig. 4b, lanes 9–10).
Finally, we examined whether we could detect and in vivo
association between raptor and the cdc2/cyclin B kinase complex.
Utilizing Hela cells stably expressing low levels of tagged raptor,
raptor immunoprecipitates from cycling or taxol-arrested cells
revealed the presence of endogenous cyclin B (Fig 4c).
Cdc2 Phosphorylation of Raptor on Ser696, Thr706 Does
Not Impact Mtorc2 Complex Formation
mTORC1 is a multi-protein complex whose function requires
proper association of all components [13]. To test whether Cdc2
phosphorylation of raptor might change the association of various
components of mTORC1, epitope tagged cDNAs of the
components of mTORC1 were expressed in HEK293E cells with
or without nocodazole. No changes in the amount of HA-GbL or
Flag-PRAS40 that co-immunoprecipitated with myc-tagged raptor
were observed with either nocodazole treatment or raptor allele
(Figure 5a). However, in whole cell lysates taken from the same
cells, endogenous 4EBP1 phosphorylation increased, which occurs
regardless of raptor allele.
It has been demonstrated that raptor acts as a scaffolding
protein between mTOR and its substrates [14,15], so we tested
whether Cdc2 phosphorylation of raptor changes the association
of known mTOR substrates S6K and 4EBP1. We observed no
cdc2 Phosphorylates Raptor
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immunoprecipitated with myc-raptor in HEK293T cells treated
with or without nocodazole regardless of raptor allele (Figure 5 b,
c), and the same is true of the reciprocal immunoprecipitations.
To confirm these results in a more physiological system, cell
lines stably over-expressing a low level of myc-tagged raptor alleles
with stable knockdown of endogenous raptor with short hairpin
RNA that targets the 39 UTR of raptor [16] were generated in
Hela cells. No changes in the ability of endogenous mTORC1
components to co-immunoprecipitate with myc-raptor were
observed with either nocodazole treatment or different raptor
alleles (Figure 5d). Taken together, these data suggest that
phosphorylation of raptor by Cdc2 does not significantly change
the composition of mTORC1 nor the ability of mTOR to signal to
downstream substrates S6K or 4EBP1 during mitosis.
Discussion
How signaling pathways coupled to nutrient uptake and
expenditure couple to the cell cycle machinery and proliferation
control has been an area of increasing investigation. The
mTORC1 signaling pathway is a critical integrator of environ-
mental inputs into protein translation and cell growth. However,
the precise role of mTORC1 signaling in mitotic progression
remains enigmatic [17].
Our previous studies indicated the presence of G2/M metabolic
checkpoint enforced by AMPK in a manner dependent on its
ability to phosphorylate raptor and suppress mTORC1 activity.
Cells expressing non-phosphorylatable alleles of raptor continued
to progress through mitosis unabated unlike those expressing wild-
type raptor, and ultimately displayed increased rates of apoptosis.
Consistent with an AMPK/mTORC1 dependent checkpoint,
AMPKa2 and its upstream kinase LKB1 were isolated in an RNAi
screen for modulators of G2/M in mammalian cells [18].
Furthermore, increased phosphorylation at the AMPKa2 activa-
tion loop was observed in a proteomic study for kinases activated
during G2/M [19] and more recently, activated AMPK has been
proposed to reside at the mitotic spindle [20], hinting at both
spatial and temporal regulation of AMPK in mitosis which may
restrict or target its regulation of mTOR to specific locations or
phases of mitosis.
Previous studies also suggest that mTOR signaling plays a
positive role in the progression through mitosis in a variety of
species. In budding yeast, a temperature sensitive allele of raptor
or rapamycin-treatment of cells both induce mitotic delay and a
prolonged G2 [21]. In contrast, in fission yeast rapamycin
induces early mitotic onset in synchronized cultures [22], though
in both yeasts, TOR activity has been tied to the control of Polo
kinase activation. Further work is needed in each of these
biological settings to further dissect the role of TOR in mitotic
control.
We demonstrate here that the mitotic kinase cdc2 directly
phosphorylates raptor during mitosis, though we have been
unable to demonstrate the contribution those phosphorylations
play to overall mitotic progression or mTORC1 signaling during
mitosis in the tumor cell settings we have examined thus far.
Importantly, our data suggests there may be additional cdc2 sites
beyond Ser696, Thr706, and Ser711 in raptor and until these
sites are fully identified, the phenotype of a fully cdc2 non-
phosphorylatable raptor remains unknown. Nontheless, the cdc2
sites in raptor may be more critical for growth control in non-
tumorigenic settings, which is an area requiring further
investigation.
One additional complicating factor is these analyses is the fact
that cdc2 has been reported to directly phosphorylate both S6K1
[23,24,25] and 4ebp1 directly [26,27]. Indeed the well-character-
ized Ser65 and Ser70 phosphorylation sites in 4e-bp1 have been
proposed to be sites of phosphorylation by cdc2, events that are
dependent on mTORC1 activity. Additionally, cdc2-dependent
phosphorylation of EE2K was shown to be suppressed by amino
acid deprivation and increased in cells lacking TSC2, conditions
that respectively serve to inhibit and stimulate mTORC1
signaling, leading to the suggesting that mTORC1 activity may
serve to contribute to cdc2-dependent regulation of EEF2K [28].
The possibility exists therefore that both cdc2 and mTORC1
kinase complexes serve to inter-regulate one another depending on
the precise timing and localization of each during different stages
of mitosis. The fact that several components of the mTORC1
pathway are targeted by cdc2 may result in no single one of them
being critical in isolation as a cdc2 target whose phosphorylation is
absolutely required for mitotic progression.
A complication of much of the previous literature studying the
effect of mTOR on G2/M progression utilizing rapamycin is that
recent finding from several labs that rapamycin does not fully
inhibit mTORC1 kinase activity. Kinase inhibitors directed at
mTOR itself yield changes in mTORC1 signaling and growth
arrest phenotypes more similar to RNAi for raptor [29,30,31].
Importantly, these effect of mTOR kinase inhibitors were
demonstrated to be independent of the mTORC2 complex and
its function [29,30]. These findings are also consistent with a
variability of rapamycin in inhibiting S6K1 signaling but not
4ebp1 phosphorylation universally in mammalian cells, unlike
RNAi or genetic deletion of raptor or mTOR [30,32]. The
inability of rapamycin to suppress 4ebp1 phosphorylation indicates
that previous studies in mammalian cells studying effects of
rapamycin on mitosis were not accounting for the full role of
mTORC1. Future studies using these new direct mTOR kinase
inhibitors will be needed to fully dissect its requirement in different
stages of mitotic progression.
Additional tools including phospho-specific antibodies which
can work for immunolocalization may better reveal where the
population of cdc2-phosphorylated raptor and 4ebp1 are during
the different stages of mitosis. Understanding how AMPK activity
and mTOR activity are controlled spatially and temporally during
mitosis will undoubtedly lead to fundamental insights into how
nutrients control cell division as well as to how protein translation
is coupled to timely cell cycle exit during differentiation or stem
cell renewal. A deeper understanding of how mTORC1 controls
cell cycle progression is essential for use of targeted mTOR
inhibitors in the treatment of cancer and many other mTOR-
related pathologies [33].
Supporting Information
Table S1 All identified in vivo phosphorylation sites in raptor.
Conservation is indicated and predicted kinases from Scansite are
listed in black. Reported in vivo kinases are indicated in red.
Found at: doi:10.1371/journal.pone.0009197.s001 (0.76 MB TIF)
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